Summary
Elevance Health, Inc. (formerly WellPoint, Inc.) issued a Form 8-K on March 12, 2013, to disclose information shared with securities analysts and investors during meetings scheduled between March 12 and March 29, 2013. The primary purpose of this disclosure was to reaffirm the company's full-year 2013 net income per share guidance. Management confirmed their expectation that full-year 2013 net income per share would be at least $7.60. This guidance explicitly includes the anticipated integration costs associated with the prior acquisition of Amerigroup. Investors should note that this 8-K serves as a means of communication regarding forward-looking statements and does not alter the 'filed' status of information for regulatory purposes under Section 18 of the Exchange Act.
Key Highlights
- 1Elevance Health (then WellPoint) reaffirmed its full-year 2013 net income per share guidance.
- 2The reaffirmed guidance was set at a minimum of $7.60 per share.
- 3This guidance explicitly accounts for integration costs related to the Amerigroup acquisition.
- 4The company was scheduled to meet with securities analysts and investors from March 12 to March 29, 2013.
- 5The 8-K filing serves as a Regulation FD disclosure, ensuring broad dissemination of the information.
- 6The filing includes a comprehensive safe harbor statement for forward-looking statements, detailing various risks and uncertainties.